Irlande - anglais - HPRA (Health Products Regulatory Authority)

dallas burston ashbourne ltd. - venlafaxine hydrochloride - tablet prolonged release - 225 milligram

Irlande - anglais - HPRA (Health Products Regulatory Authority)

dallas burston ashbourne ltd. - venlafaxine hydrochloride - tablet prolonged release - 75 milligram

Irlande - anglais - HPRA (Health Products Regulatory Authority)

macarthys laboratories limited - venlafaxine - prolonged-release tablet - 37.5 milligram(s) - other antidepressants; venlafaxine

Irlande - anglais - HPRA (Health Products Regulatory Authority)

macarthys laboratories limited - venlafaxine - prolonged-release tablet - 75 milligram(s) - other antidepressants; venlafaxine

Irlande - anglais - HPRA (Health Products Regulatory Authority)

macarthys laboratories limited - venlafaxine - prolonged-release tablet - 150 milligram(s) - other antidepressants; venlafaxine

Irlande - anglais - HPRA (Health Products Regulatory Authority)

macarthys laboratories limited - venlafaxine - prolonged-release tablet - 225 milligram(s) - other antidepressants; venlafaxine

Égypte - anglais - EDA (Egyptian Drug Authority)

rexcel - coated tablet - 75 mg

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - venlafaxine hydrochloride - modified-release tablet - 300mg

États-Unis - anglais - NLM (National Library of Medicine)

dr. reddy's laboratories limited - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 25 mg - venlafaxine tablets are indicated for the treatment of major depressive disorder. the efficacy of venlafaxine hydrochloride in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iii-r category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the efficacy of venlaf

États-Unis - anglais - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg